ESTRO: ADT Plus Radiotherapy Improve Prostate Cancer Outcomes

Professor Vincenzo Valentini, president of ESTRO and a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, commented in a statement: The results from this trial are important and practice-changing. It is clear that an additional six months of hormonal treatment in addition to radiotherapy improves the outcome for men with localised prostate cancer. This option should now be considered for all these men with prostate cancer that is at risk of growing and spreading.

The combination of radiotherapy and androgen deprivation therapy (ADT) is more effective than radiotherapy alone for preventing disease recurrence in men with localised prostate cancer, according to research findings presented at the European Society for Radiotherapy and Oncology (ESTRO) 33rd annual congress in Vienna, Austria.

Michael Bolla (Grenoble University Hospital, France), the study’s lead author, said that the findings needed to be taken into account in daily clinical practice. He said in a statement: “[D]uring multidisciplinary team meetings to discuss a patient’s treatment, this combined treatment approach should be one of the options proposed for men with localised prostate cancer that has an intermediate or high risk of growing and spreading.”

The “EORTC 22991” trial was conducted in 14 countries and involved 819 men with intermediate- or high-risk localised prostate cancer. They were randomly assigned to receive three-dimensional conformal radiotherapy with or without ADT.

Read the complete report here:

Source: medwireNews